Nike Inc (NKE) beat Q3 earnings, while it met revenue targets. The sneaker maker reported earnings of 68 cents on revenue of $9.61 billion. Analysts had expected the company to post earnings of $0.65 on revenue of $9.61 billion. Nike stock, which ended the day by increasing 1.52% to $88.01, dropped about 3% during the extended-hours of trading.
“The Consumer Direct Offense is delivering broad-based growth across all four of our geographies, led by continued momentum in China,” said Andy Campion, CFO. “We will continue investing in key capabilities to drive NIKE’s digital transformation and fuel strong profitable growth into next fiscal year and beyond,” he added.
Last month, Nike’s Board of Directors declared a quarterly cash dividend of $0.22 per share on the company’s outstanding Class A and Class B common Stock payable on April 1, 2019 to shareholders of record as of March 4, 2019.
North America continues to be a challenging market for most sportswear companies, due to the growing competition and people’s fast-changing shopping habits.
Nike’s peer Under Armour (UA, UAA) last month reported a 2% increase in fourth-quarter revenues to $1.4 billion, which resulted in flat earnings. A further slump in the Americas was more than offset by the positive outcome in other markets.
Nike was in news for the wrong reasons recently, after Duke basketball player Zion Williamson’s sneaker exploded during a game, causing minor injuries to the player. However, the incident had minimal impact on the stock, which bounced back quickly from the initial dip that followed the report.
On Tuesday, shares of Nike hit a yearly high ($88.59). In Thursday’s regular trading session, Nike stock almost hit the 52-week high with a day’s high of $88.12. The stock has gained 19% since the beginning of this year.
We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips
Most Popular
Cost reduction has become a priority for FedEx (FDX) after a challenging quarter
Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for
Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know
After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG
Stock Watch: Is Darden Restaurants a good buy after earnings?
After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many
